ABSTRACT
Seventeen days after double lung transplantation, a 56-year-old patient with idiopathic pulmonary fibrosis developed respiratory distress. Imaging revealed bilateral pulmonary infiltrates with pleural effusions and physical examination demonstrated sternal instability. Broad-spectrum antibacterial and antifungal therapy was initiated and bilateral thoracotomy tubes were placed. Both right and left pleural cultures grew a mold subsequently identified as Scopulariopsis brumptii. The patient underwent pleural irrigation and sternal debridement three times but pleural and wound cultures continued to grow S. brumptii. Despite treatment with five antifungal agents, the patient succumbed to his illness 67 days after transplantation. Autopsy confirmed the presence of markedly invasive fungal disease and pleural rind formation. The patient's organ donor had received bilateral thoracostomy tubes during resuscitation in a wilderness location. There were no visible pleural abnormalities at the time of transplantation. However, the patient's clinical course and the location of the infection, in addition to the lack of similar infection in other organ recipients, strongly suggest that Scopulariopsis was introduced into the pleural space during prehospital placement of thoracostomy tubes. This case of lethal infection transmitted through transplantation highlights the unique risk of using organs from donors who are resuscitated in an outdoor location.
Subject(s)
Graft Rejection/etiology , Idiopathic Pulmonary Fibrosis/surgery , Lung Transplantation/adverse effects , Mycoses/transmission , Postoperative Complications , Scopulariopsis/pathogenicity , Tissue and Organ Procurement , Fatal Outcome , Humans , Idiopathic Pulmonary Fibrosis/microbiology , Male , Middle Aged , Mycoses/diagnosis , Mycoses/drug therapy , Scopulariopsis/isolation & purification , Tissue Donors , Transplant RecipientsABSTRACT
Macrophage derived-endothelin-1 (ET-1) has been suggested to contribute to a number of chronic lung diseases. Whether the ET-1 cascade from non-vascular sources (inflammatory cells) also contributes to pulmonary artery hypertension (PAH) and in particular to heritable PAH (HPAH) with known bone morphogenetic protein type 2 receptor (BMPR2) mutations is not known. We tested this notion using bone marrow-derived macrophages (BMDM; precursors of tissue macrophages) isolated from ROSA26rtTAXTetO(7)-tet-BMPR2(R899X) mice (model of PAH with universal expression of a mutated BMPR2 gene) with and without activation by LPS and in human lung tissue from HPAH with BMPR2 mutations and idiopathic PAH (IPAH). At baseline ET(A) and ET(B) receptors and endothelin converting enzyme (ECE) gene expression was reduced in BMPR2 mutant BMDM compared with controls. In control BMDM, LPS resulted in increased ppET-1 gene expression and ET-1 in culture media, whereas ET(A) and ET(B) receptor and ECE gene expression was decreased. These findings were more severe in BMPR2 mutant BMDM. Antagonism of the ET(B) receptor resulted in increased ET-1 in the media, suggesting that decreased ET-1 uptake by the ET(B) receptor contributes to the elevation. While ET-1 expression was demonstrated in lung macrophages from controls and IPAH and HPAH patients, ET(A) and ET(B) expression was decreased in the HPAH, but not IPAH, patients compared with controls. We conclude that reduced expression of macrophage ET-1 receptors in HPAH increases lung ET-1 and may contribute to the pathogenesis and maintenance of HPAH. This is the first description of protein expression that distinguishes HPAH from IPAH in patients.
Subject(s)
Bone Morphogenetic Protein Receptors, Type II/genetics , Endothelin-1/metabolism , Hypertension, Pulmonary/genetics , Hypertension, Pulmonary/metabolism , Macrophages, Alveolar/metabolism , Mutation , Adolescent , Adult , Aged , Animals , Aspartic Acid Endopeptidases/metabolism , Endothelin-Converting Enzymes , Female , Gene Expression , Humans , Macrophages/metabolism , Male , Metalloendopeptidases/metabolism , Mice , Mice, Mutant Strains , Microscopy, Confocal , Middle Aged , Receptor, Endothelin A/metabolism , Receptor, Endothelin B/metabolism , Tissue Distribution , Young AdultABSTRACT
Bone morphogenetic protein receptor type 2 (BMPR2) gene mutations are a major risk factor for heritable pulmonary arterial hypertension (HPAH), an autosomal dominant fatal disease. We have previously shown that BMPR2 transcripts that contain premature termination codon (PTC) mutations are rapidly and nearly completely degraded through nonsense mediated decay (NMD). Here we report a unique PTC mutation (W13X) that did not behave in the predicted manner. We found that patient-derived cultured lymphocytes (CLs) contained readily detectable levels of the PTC-containing transcript. Further analysis suggested that this transcript escaped NMD by translational re-initiation at a downstream Kozak sequence, resulting in the omission of 173 amino acids. Treatment of CLs containing the PTC with an aminoglycoside decreased the truncated protein levels, with a reciprocal increase in full-length BMPR2 protein and, importantly, BMPR-II signaling. This is the first demonstration of aminoglycoside-mediated 'repair' of a BMPR2 mutation at the protein level in patient-derived cells and has obvious implications for treatment of HPAH where no disease-specific treatment options are available. Our data also suggest the need for a more thorough characterization of mutations prior to labeling them as haploinsufficient or dominant negative based simply on sequencing data.
Subject(s)
Bone Morphogenetic Protein Receptors, Type II/genetics , Codon, Nonsense , Hypertension, Pulmonary/genetics , Mutation , Aminoglycosides/therapeutic use , Female , Humans , Hypertension, Pulmonary/drug therapy , Lymphocytes , Male , PedigreeABSTRACT
RATIONALE: Mounting data suggest that immune cell abnormalities participate in the pathogenesis of pulmonary arterial hypertension (PAH). OBJECTIVE: To determine whether the T lymphocyte subset composition in the systemic circulation and peripheral lung is altered in PAH. METHODS: Flow cytometric analyses were performed to determine the phenotypic profile of peripheral blood lymphocytes in idiopathic PAH (IPAH) patients (n=18) and healthy controls (n=17). Immunocytochemical analyses of lymphocytes and T cell subsets were used to examine lung tissue from PAH patients (n=11) and controls (n=11). MEASUREMENTS AND MAIN RESULTS: IPAH patients have abnormal CD8+ T lymphocyte subsets, with a significant increase in CD45RA+ CCR7- peripheral cytotoxic effector-memory cells (p=0.02) and reduction of CD45RA+ CCR7+ naive CD8+ cells versus controls (p=0.001). Further, IPAH patients have a higher proportion of circulating regulatory T cells (T(reg)) and 4-fold increases in the number of CD3+ and CD8+ cells in the peripheral lung compared with controls (p<0.01). CONCLUSIONS: Alterations in circulating T cell subsets, particularly CD8+ T lymphocytes and CD4+ T(reg), in patients with PAH suggest that a dysfunctional immune system contributes to disease pathogenesis. A preponderance of CD3+ and CD8+ T lymphocytes in the peripheral lung of PAH patients supports this concept.
Subject(s)
Hypertension, Pulmonary/immunology , Lung/immunology , T-Lymphocyte Subsets/immunology , Adult , Female , Flow Cytometry , Humans , Immunologic Memory/immunology , Lung/chemistry , Male , Middle AgedABSTRACT
Mutations in bone morphogenetic protein receptor type 2 (BMPR2) cause familial pulmonary arterial hypertension (FPAH), but the penetrance is reduced and females are significantly overrepresented. In addition, gene expression data implicating the oestrogen-metabolising enzyme CYP1B1 suggests a detrimental role of oestrogens or oestrogen metabolites. We examined genetic and metabolic markers of altered oestrogen metabolism in subjects with a BMPR2 mutation. Genotypes for CYP1B1 Asn453Ser (N453S) were determined for 140 BMPR2 mutation carriers (86 females and 54 males). Nested from those subjects, a case-control study of urinary oestrogen metabolite levels (2-hydroxyoestrogen (2-OHE) and 16alpha-hydroxyoestrone (16alpha-OHE(1))) was conducted in females (five affected mutation carriers versus six unaffected mutation carriers). Among females, there was four-fold higher penetrance among subjects homozygous for the wild-type genotype (N/N) than those with N/S or S/S genotypes (p = 0.005). Consistent with this finding, the 2-OHE/16alpha-OHE(1) ratio was 2.3-fold lower in affected mutation carriers compared to unaffected mutation carriers (p = 0.006). Our findings suggest that variations in oestrogens and oestrogen metabolism modify FPAH risk. Further investigation of the role of oestrogens in this disease with profound sex bias may yield new insights and, perhaps, therapeutic interventions.
Subject(s)
Bone Morphogenetic Protein Receptors, Type II/genetics , Estrogens/metabolism , Hypertension/diagnosis , Hypertension/epidemiology , Pulmonary Artery/physiopathology , Adult , Aged , Bone Morphogenetic Protein Receptors, Type II/metabolism , Case-Control Studies , Cohort Studies , Female , Genotype , Heterozygote , Humans , Hypertension/metabolism , Male , Middle Aged , Mutation , Polymorphism, Genetic , Sex FactorsABSTRACT
Pulmonary arterial hypertension (PAH) is a fatal disease associated with severe remodeling of the large and small pulmonary arteries. Increased accumulation of inflammatory cells and apoptosis-resistant cells are contributing factors. Proliferative apoptosis-resistant cells expressing CD133 are increased in the circulation of PAH patients. Circulating cells can contribute to tissue repair via cell fusion and heterokaryon formation. We therefore hypothesized that in the presence of increased leukocytes and CD133-positive (CD133(pos)) cells in PAH lung tissue, cell fusion and resulting genomic instability could account for abnormal cell proliferation and the genesis of vascular lesions. We performed analyses of CD45/CD133 localization, cell fusion, and proliferation during late-stage PAH in human lung tissue from control subjects and subjects with idiopathic (IPAH) and familial (FPAH) PAH. Localization, proliferation, and quantitation of cell populations in individual patients were performed by immunolocalization. The occurrence of cellular fusion in vascular lesions was analyzed in lung tissue by fluorescence in situ hybridization. We found the accumulation of CD45(pos) leukocytic cells in the tissue parenchyma and perivascular regions in PAH patients and less frequently observed myeloid cells (CD45/CD11b). CD133(pos) cells were detected in occlusive lesions and perivascular areas in those with PAH and were more numerous in those with IPAH lesions than in FPAH lesions. Cells coexpressing CD133 and smooth muscle alpha-actin were occasionally observed in occlusive lesions and perivascular areas. Proliferating cells were more prominent in IPAH lesions and colocalized with CD45 or CD133. We found no evidence of increased ploidy to suggest cell fusion. Taken together, these data suggest that abnormal lesion formation in PAH occurs in the absence of cell fusion.
Subject(s)
Apoptosis , Hypertension, Pulmonary/pathology , Lung/pathology , Myeloid Cells/pathology , Pulmonary Artery/pathology , AC133 Antigen , Adult , Antigens, CD/metabolism , Cell Fusion , Cell Proliferation , Child , Female , Giant Cells/metabolism , Giant Cells/pathology , Glycoproteins/metabolism , Humans , Hypertension, Pulmonary/metabolism , Leukocyte Common Antigens/biosynthesis , Lung/metabolism , Male , Middle Aged , Myeloid Cells/metabolism , Peptides/metabolism , Pulmonary Artery/metabolismABSTRACT
The frequency and complications of respiratory viral infections (RVI) were studied in 50 ambulatory lung transplant patients during a single winter season, using viral antigens, viral cultures and PCR of nasal washes or bronchoalveolar lavages. Patients' survival, episodes of acute rejection and occurrence of bronchiolitis obliterans (BO) or BO syndrome (BOS) were monitored for 1 yr after the study. Overall, 32 (64%) patients had 49 symptomatic episodes. Documented infections included eight due to respiratory syncytial virus (RSV), one due to parainfluenza virus (PIV) and 10 due to influenza (FLU). Four of the FLU infections were serological rises without symptoms. Overall, 17 (34%) patients had documented viral infection; four patients had lower respiratory involvement and two (one RSV, one PIV) were hospitalised for aerosolised ribavirin treatment. After 1 yr there were three (6%) deaths unrelated to RVI. BO or BOS had occurred in one (6%) out of 17 patients with and three (12%) out of 33 without RVI. Respiratory viruses infected one-third of ambulatory lung transplant recipients in a single season. In conclusion, respiratory viral infection was not associated with subsequent graft dysfunction. Larger prospective studies are required to better define the acute and long-term morbidity of these infections.
Subject(s)
Bronchiolitis Obliterans/diagnosis , Bronchiolitis Obliterans/etiology , Lung Transplantation/adverse effects , Respiratory Tract Infections/diagnosis , Respiratory Tract Infections/etiology , Respiratory Tract Infections/virology , Virus Diseases/diagnosis , Virus Diseases/etiology , Adult , Animals , Cell Line , Female , Humans , Immunosuppressive Agents/pharmacology , Influenza, Human/complications , Macaca mulatta , Male , Middle Aged , Paramyxoviridae/metabolism , Prospective Studies , Respiratory Syncytial Viruses/metabolism , Seasons , Syndrome , Treatment OutcomeABSTRACT
Everolimus is a proliferation signal inhibitor with immunosuppressive activity that may reduce the rate of progression of chronic rejection, bronchiolitis obliterans syndrome (BOS), after lung transplantation. In a randomized, double-blind clinical trial, 213 BOS-free maintenance patients received everolimus (3 mg/day) or azathioprine (AZA, 1-3 mg/kg/day) in combination with cyclosporine and corticosteroids. The prospectively defined primary endpoint was the incidence of efficacy failure (decline in FEV1 >15%[deltaFEV1 >15%], graft loss, death or loss to follow-up) at 12 months. Incidence of efficacy failure at 12 months was significantly lower in the everolimus group than AZA (21.8% vs. 33.9%; p = 0.046); at 24 months, rates of efficacy failure became similar between the groups. At 12 months, the everolimus group had significantly reduced incidences of deltaFEV1 >15%, deltaFEV1 >15% with BOS, and acute rejection. At 24 months, only incidence of acute rejection remained significantly less in the everolimus group. Treatment discontinuations (particularly due to adverse events), serious adverse events and high serum creatinine values were more common with everolimus. For the first time, a drug has demonstrated significant slowing of loss in lung function, suggesting that patients kept on prolonged maintenance treatment with everolimus may benefit from replacing AZA with everolimus 3 months after lung transplantation.
Subject(s)
Azathioprine/therapeutic use , Bronchiolitis Obliterans/prevention & control , Graft Rejection/prevention & control , Immunosuppressive Agents/therapeutic use , Lung Transplantation , Sirolimus/analogs & derivatives , Adrenal Cortex Hormones/therapeutic use , Adult , Azathioprine/adverse effects , Cyclosporine/therapeutic use , Double-Blind Method , Drug Therapy, Combination , Everolimus , Humans , Immunosuppression Therapy , Immunosuppressive Agents/adverse effects , Lung/pathology , Lung/physiopathology , Male , Middle Aged , Sirolimus/adverse effects , Sirolimus/therapeutic use , SyndromeABSTRACT
We sought to determine if the BK and JC polyomaviruses were associated with idiopathic pulmonary fibrosis (IPF). We did not detect the BK or JC polyomaviruses in lung tissue extracts from 33 patients with IPF by using real-time PCR, which suggests that an etiologic association is unlikely.
Subject(s)
BK Virus/isolation & purification , JC Virus/isolation & purification , Lung/virology , Pulmonary Fibrosis/etiology , Humans , Polymerase Chain Reaction , Pulmonary Fibrosis/virologyABSTRACT
BACKGROUND: While idiopathic pulmonary fibrosis (IPF) is one of the most common forms of interstitial lung disease, the aetiology of IPF is poorly understood. Familial cases of pulmonary fibrosis suggest a genetic basis for some forms of the disease. Recent reports have linked genetic mutations in surfactant protein C (SFTPC) with familial forms of pulmonary fibrosis, including one large family in which a number of family members were diagnosed with usual interstitial pneumonitis (UIP), the pathological correlate to IPF. Because of this finding in familial cases of pulmonary fibrosis, we searched for SFTPC mutations in a cohort of sporadic cases of UIP and non-specific interstitial pneumonitis (NSIP). METHODS: The gene for SFTPC was sequenced in 89 patients diagnosed with UIP, 46 patients with NSIP, and 104 normal controls. RESULTS: Ten single nucleotide polymorphisms in the SFTPC sequence were found in IPF patients and not in controls. Only one of these created an exonic change resulting in a change in amino acid sequence. In this case, a T to C substitution resulted in a change in amino acid 73 of the precursor protein from isoleucine to threonine. Of the remaining polymorphisms, one was in the 5' UTR, two were exonic without predicted amino acid sequence changes, and six were intronic. One intronic mutation suggested a potential enhancement of a splicing site. CONCLUSIONS: Mutations in SFTPC are identified infrequently in this patient population. These findings indicate that SFTPC mutations do not contribute to the pathogenesis of IPF in the majority of sporadic cases.
Subject(s)
Lung Diseases, Interstitial/genetics , Mutation/genetics , Pulmonary Surfactant-Associated Protein C/genetics , Female , Gene Amplification , Heterozygote , Humans , Male , Middle Aged , Polymorphism, GeneticABSTRACT
The purposes of this work were to estimate regional and global pulmonary perfusion and display pulmonary vasculature in 10 postoperative lung transplant patients using breath-hold, contrast-enhanced (0.2 mmol/kg, Gd DTPA-BMA, Omniscan, Nycomed, Inc., Princeton, NJ), three-dimensional (3D) magnetic resonance angiography (MRA) with specially designed double-variable-angle uniform signal excitation (VUSE) radio frequency (RF) pulses. Double-VUSE scans imaged both lungs simultaneously during contrast agent injection and provided both qualitative and quantitative information about pulmonary perfusion. Double-VUSE pulses clearly displayed healthy and diseased vessels. There was a strong correlation between contrast-enhanced double-VUSE MRA flow estimates and those measured from nuclear scans for global or whole lung (R(2) = 0.95; P = 0.000002) and upper, central, and lower thirds of the lung (R(2) = 0.89, 0.92, and 0.86, respectively; P < 0.001 for each region). In conclusion, 3D MRA using VUSE pulses in combination with a contrast agent is a valuable tool for the assessment of pulmonary perfusion that simultaneously acquires data for both the qualitative display of pulmonary vessels and the quantification of regional and global differential pulmonary blood flow.
Subject(s)
Magnetic Resonance Angiography , Pulmonary Circulation , Adult , Aged , Contrast Media , Female , Gadolinium DTPA , Humans , Image Enhancement , Lung/blood supply , Lung Transplantation , Male , Middle Aged , Pulsatile Flow/physiologyABSTRACT
Familial primary pulmonary hypertension (FPPH) is a well described clinical entity in which the disease occurs in at least two first degree relatives. It is clinically and pathologically indistinguishable from sporadic PPH. Mutations in the gene which encodes bone morphogenetic receptor 2 have recently been discovered in familial and sporadic PPH. This review discusses the basic clinical and genetic features of FPPH, and describes the research that led to the discovery of the disease-causing gene. Potential mechanisms of disease are also discussed, as well as implications for future investigations.
Subject(s)
Hypertension, Pulmonary/genetics , Bone Morphogenetic Protein Receptors, Type II , Female , Genetic Linkage , Germ-Line Mutation , Hemodynamics , Humans , Hypertension, Pulmonary/epidemiology , Hypertension, Pulmonary/pathology , Incidence , Male , Pedigree , Protein Serine-Threonine Kinases/genetics , Receptors, Cell Surface/genetics , Sex FactorsABSTRACT
Mediastinal fibrosis is the least common, but the most severe, late complication of histoplasmosis. It should be differentiated from the many other less-severe mediastinal complications of histoplasmosis, and from other causes of mediastinal fibrosis. Posthistoplasmosis mediastinal fibrosis is characterized by invasive, calcified fibrosis centered on lymph nodes, which, by definition, occludes major vessels or airways.
Subject(s)
Histoplasmosis/pathology , Mediastinal Diseases/pathology , Adult , Diagnosis, Differential , Female , Fibrosis/diagnostic imaging , Fibrosis/etiology , Fibrosis/pathology , Histoplasmosis/complications , Histoplasmosis/prevention & control , Humans , Male , Mediastinal Diseases/diagnostic imaging , Mediastinal Diseases/etiology , Tomography, X-Ray ComputedABSTRACT
Mediastinal fibrosis is a rare consequence of infection with the fungus Histoplasma capsulatum that can lead to occlusion of large pulmonary arteries and veins and mainstem bronchi. Medical and surgical treatments for this disorder have been ineffective. We describe successful treatment for central pulmonary arterial and venous obstruction due to mediastinal fibrosis in four patients using percutaneously placed intravascular stents. Patients were severely limited, World Health Organization functional class III or IV. At the time of right and left heart catheterization, stents were placed in pulmonary arteries (n = 1), veins (n = 2), or both (n = 1) to relieve vascular obstruction resulting from mediastinal fibrosis. Immediate hemodynamic and clinical improvement was observed in all patients. Three of the four patients have had sustained improvement in exercise tolerance, from 3.5 mo to 4.5 yr after stent placement. The only complication was a self-limited pulmonary hemorrhage in one patient. Our initial experience suggests that percutaneous stent placement to relieve central pulmonary arterial or venous obstruction due to mediastinal fibrosis is an effective new treatment modality.
Subject(s)
Histoplasmosis/complications , Mediastinal Diseases/complications , Mediastinum/pathology , Mediastinum/surgery , Pulmonary Artery/surgery , Pulmonary Veins/surgery , Stents , Adult , Angiography , Cardiac Catheterization , Constriction, Pathologic/diagnosis , Constriction, Pathologic/microbiology , Constriction, Pathologic/surgery , Exercise Test , Female , Fibrosis , Follow-Up Studies , Histoplasmosis/microbiology , Humans , Male , Mediastinal Diseases/microbiology , Mediastinum/blood supply , Middle Aged , Phlebography , Severity of Illness Index , Treatment OutcomeABSTRACT
BACKGROUND: Most patients with primary pulmonary hypertension are thought to have sporadic, not inherited, disease. Because clinical disease develops in only 10 to 20 percent of persons carrying the gene for familial primary pulmonary hypertension, we hypothesized that many patients with apparently sporadic primary pulmonary hypertension may actually have familial primary pulmonary hypertension. METHODS: In a study conducted over 20 years, we developed a registry of 67 families affected by familial primary pulmonary hypertension. Through patient referrals, extensive family histories, and correlation of family pedigrees, we discovered shared ancestry among five subfamilies. We established the diagnosis of primary pulmonary hypertension by direct evaluation of patients and review of autopsy material and medical records. We assessed some family members for mutations in the gene encoding bone morphogenetic protein receptor II (BMPR2), which has recently been found to cause familial primary pulmonary hypertension. RESULTS: We linked five separately identified subfamilies that included 394 known members spanning seven generations, which were traced back to a founding couple in the mid-1800s. Familial primary pulmonary hypertension has been diagnosed in 18 family members, 12 of whom were first thought to have sporadic disease. The conditions of 7 of the 18 were initially misdiagnosed as other cardiopulmonary diseases. Six members affected with familial primary pulmonary hypertension and 6 of 10 at risk for carriage have been undergone genotype analysis, and they have the same mutation in BMPR2, a transversion of thymine to guanine at position 354 in exon 3. CONCLUSIONS: Many cases of apparently sporadic primary pulmonary hypertension may be familial. Failure to detect familial primary pulmonary hypertension results from incomplete expression within families, skipped generations, and incomplete family pedigrees. The recent discovery of mutations in BMPR2 should make it possible to identify those with susceptibility to disease.
Subject(s)
Hypertension, Pulmonary/genetics , Mutation, Missense , Protein Serine-Threonine Kinases/genetics , Adult , Bone Morphogenetic Protein Receptors, Type II , Bone Morphogenetic Proteins/physiology , Chromosome Mapping , Chromosomes, Human, Pair 2 , Diagnostic Errors , Female , Heterozygote , Humans , Hypertension, Pulmonary/diagnosis , Male , Pedigree , Point MutationABSTRACT
BACKGROUND: Most patients with familial primary pulmonary hypertension have defects in the gene for bone morphogenetic protein receptor II (BMPR2), a member of the transforming growth factor beta (TGF-beta) superfamily of receptors. Because patients with hereditary hemorrhagic telangiectasia may have lung disease that is indistinguishable from primary pulmonary hypertension, we investigated the genetic basis of lung disease in these patients. METHODS: We evaluated members of five kindreds plus one individual patient with hereditary hemorrhagic telangiectasia and identified 10 cases of pulmonary hypertension. In the two largest families, we used microsatellite markers to test for linkage to genes encoding TGF-beta-receptor proteins, including endoglin and activin-receptor-like kinase 1 (ALK1), and BMPR2. In subjects with hereditary hemorrhagic telangiectasia and pulmonary hypertension, we also scanned ALK1 and BMPR2 for mutations. RESULTS: We identified suggestive linkage of pulmonary hypertension with hereditary hemorrhagic telangiectasia on chromosome 12q13, a region that includes ALK1. We identified amino acid changes in activin-receptor-like kinase 1 that were inherited in subjects who had a disorder with clinical and histologic features indistinguishable from those of primary pulmonary hypertension. Immunohistochemical analysis in four subjects and one control showed pulmonary vascular endothelial expression of activin-receptor-like kinase 1 in normal and diseased pulmonary arteries. CONCLUSIONS: Pulmonary hypertension in association with hereditary hemorrhagic telangiectasia can involve mutations in ALK1. These mutations are associated with diverse effects, including the vascular dilatation characteristic of hereditary hemorrhagic telangiectasia and the occlusion of small pulmonary arteries that is typical of primary pulmonary hypertension.
Subject(s)
Hypertension, Pulmonary/genetics , Mutation , Protein Serine-Threonine Kinases/genetics , Telangiectasia, Hereditary Hemorrhagic/genetics , Activin Receptors , Adult , Bone Morphogenetic Protein Receptors, Type II , Child , Child, Preschool , Chromosome Mapping , Chromosomes, Human, Pair 12 , Female , Humans , Hypertension, Pulmonary/complications , Hypertension, Pulmonary/pathology , Lung/pathology , Male , Microsatellite Repeats , Middle Aged , Mutation, Missense , Pedigree , Signal Transduction , Telangiectasia, Hereditary Hemorrhagic/complications , Transforming Growth Factor beta/genetics , Transforming Growth Factor beta/metabolismABSTRACT
Paradoxical systemic air embolism (PAE) occurring as a complication of right-to-left intracardiac shunting during evaluation and treatment of pulmonary hypertension (PH) has not been previously reported. We report four cases of PH-associated PAE recently encountered at our center. Two patients with PH experienced transient neurologic deficits during agitated-saline contrast echocardiography (ASCE), and a patent foramen ovale was subsequently diagnosed in both patients. Two patients with Eisenmenger's syndrome (ES), while receiving epoprostenol via multilumen catheters, experienced transient neurologic deficits while flushing the unused port of the catheter. No patient experienced permanent neurologic deficits. We conclude that ASCE poses a risk for PAE in patients with PH and clinically silent, previously undetected, right-to-left intracardiac shunts, and that multilumen catheters used for long-term epoprostenol therapy in ES carry a risk of PAE.
Subject(s)
Embolism, Air/etiology , Hypertension, Pulmonary/complications , Adult , Female , Humans , Iatrogenic Disease , Male , Middle AgedABSTRACT
Primary pulmonary hypertension (PPH) is a disease of unknown etiology characterized by lumen-obliterating endothelial cell proliferation and vascular smooth muscle hypertrophy of the small precapillary pulmonary arteries. Because the vascular lesions are homogeneously distributed throughout the entire lung, we propose that a tissue fragment of the lung is representative of the whole lung. RNA extracted from the fragments is likely to provide meaningful information regarding the changes in gene expression pattern in PPH when compared with structurally normal lung tissue. We hypothesize that the lung tissue gene expression pattern of patients with PPH has a characteristic profile when compared with the gene expression pattern of structurally normal lungs and that this characteristic gene expression profile provides new insights into the pathobiology of PPH. Using oligonucleotide microarray technology, we characterized the expression pattern in the lung tissue obtained from 6 patients with primary pulmonary hypertension (PPH)-including 2 patients with the familial form of PPH (FPPH)-and from 6 patients with histologically normal lungs. For the data analysis, gene clusters were generated and the gene expression pattern differences between PPH and normal lung tissue and between PPH and FPPH lung tissue were compared. All PPH lung tissue samples showed a decreased expression of genes encoding several kinases and phosphatases, whereas several oncogenes and genes coding for ion channel proteins were upregulated in their expression. Importantly, we could distinguish by pattern comparison between sporadic PPH and FPPH, because alterations in the expression of transforming growth factor-beta receptor III, bone morphogenic protein 2, mitogen-activated protein kinase kinase 5, RACK 1, apolipoprotein C-III, and the gene encoding the laminin receptor 1 were only found in the samples from patients with sporadic PPH, but not in FPPH samples. We conclude that the microarray gene expression technique is a new and useful molecular tool that provides novel information pertinent to a better characterization and understanding of the pathobiology of the distinct clinical phenotypes of pulmonary hypertension.